Gain Therapeutics (GANX) Competitors $1.97 +0.16 (+8.84%) Closing price 08/22/2025 04:00 PM EasternExtended Trading$1.94 -0.03 (-1.52%) As of 08/22/2025 07:42 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock GANX vs. SCPH, ALLO, SGMT, SOPH, AARD, FENC, GALT, ALEC, GNFT, and TVRDShould you be buying Gain Therapeutics stock or one of its competitors? The main competitors of Gain Therapeutics include scPharmaceuticals (SCPH), Allogene Therapeutics (ALLO), Sagimet Biosciences (SGMT), SOPHiA GENETICS (SOPH), Aardvark Therapeutics (AARD), Adherex Technologies (FENC), Galectin Therapeutics (GALT), Alector (ALEC), GENFIT (GNFT), and Tvardi Therapeutics (TVRD). These companies are all part of the "pharmaceutical products" industry. Gain Therapeutics vs. Its Competitors scPharmaceuticals Allogene Therapeutics Sagimet Biosciences SOPHiA GENETICS Aardvark Therapeutics Adherex Technologies Galectin Therapeutics Alector GENFIT Tvardi Therapeutics scPharmaceuticals (NASDAQ:SCPH) and Gain Therapeutics (NASDAQ:GANX) are both small-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their risk, valuation, media sentiment, analyst recommendations, profitability, earnings, dividends and institutional ownership. Do insiders and institutionals believe in SCPH or GANX? 89.5% of scPharmaceuticals shares are owned by institutional investors. Comparatively, 12.0% of Gain Therapeutics shares are owned by institutional investors. 4.8% of scPharmaceuticals shares are owned by insiders. Comparatively, 7.2% of Gain Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term. Do analysts rate SCPH or GANX? scPharmaceuticals currently has a consensus target price of $14.00, indicating a potential upside of 188.66%. Gain Therapeutics has a consensus target price of $7.80, indicating a potential upside of 295.94%. Given Gain Therapeutics' higher probable upside, analysts clearly believe Gain Therapeutics is more favorable than scPharmaceuticals.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score scPharmaceuticals 0 Sell rating(s) 0 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 3.00Gain Therapeutics 0 Sell rating(s) 0 Hold rating(s) 5 Buy rating(s) 0 Strong Buy rating(s) 3.00 Is SCPH or GANX more profitable? Gain Therapeutics has a net margin of 0.00% compared to scPharmaceuticals' net margin of -183.55%. Gain Therapeutics' return on equity of -289.10% beat scPharmaceuticals' return on equity.Company Net Margins Return on Equity Return on Assets scPharmaceuticals-183.55% -1,647.86% -71.76% Gain Therapeutics N/A -289.10%-155.11% Which has more volatility and risk, SCPH or GANX? scPharmaceuticals has a beta of 0.4, suggesting that its stock price is 60% less volatile than the S&P 500. Comparatively, Gain Therapeutics has a beta of 0.1, suggesting that its stock price is 90% less volatile than the S&P 500. Does the media refer more to SCPH or GANX? In the previous week, scPharmaceuticals and scPharmaceuticals both had 1 articles in the media. scPharmaceuticals' average media sentiment score of 1.93 beat Gain Therapeutics' score of 1.09 indicating that scPharmaceuticals is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment scPharmaceuticals 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive Gain Therapeutics 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Which has higher valuation & earnings, SCPH or GANX? Gain Therapeutics has lower revenue, but higher earnings than scPharmaceuticals. Gain Therapeutics is trading at a lower price-to-earnings ratio than scPharmaceuticals, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioscPharmaceuticals$36.33M7.12-$85.15M-$1.81-2.68Gain Therapeutics$50K1,416.43-$20.41M-$0.63-3.13 SummaryGain Therapeutics beats scPharmaceuticals on 8 of the 14 factors compared between the two stocks. Get Gain Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for GANX and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding GANX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart GANX vs. The Competition Export to ExcelMetricGain TherapeuticsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$70.82M$2.53B$5.81B$9.76BDividend YieldN/A1.67%4.39%4.06%P/E Ratio-3.1322.9031.3626.05Price / Sales1,416.43516.56387.8788.42Price / CashN/A179.1038.0259.36Price / Book19.705.939.536.60Net Income-$20.41M$31.83M$3.26B$265.65M7 Day Performance13.87%1.89%2.14%2.00%1 Month Performance17.26%1.62%3.22%0.46%1 Year Performance52.71%9.25%30.18%18.88% Gain Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)GANXGain Therapeutics2.3893 of 5 stars$1.97+8.8%$7.80+295.9%+52.7%$70.82M$50K-3.1320SCPHscPharmaceuticals4.5381 of 5 stars$4.78+3.9%$14.00+192.9%-9.7%$245.17M$49.97M-2.6430Positive NewsShort Interest ↓ALLOAllogene Therapeutics2.6567 of 5 stars$1.09-0.9%$8.44+674.7%-54.4%$244.07M$20K-0.98310SGMTSagimet Biosciences2.8982 of 5 stars$7.55-1.6%$25.67+240.0%+141.8%$235.28M$2M-4.138SOPHSOPHiA GENETICS2.9469 of 5 stars$3.49+0.6%$8.00+129.2%-3.5%$234.50M$65.17M-7.93520Positive NewsGap UpAARDAardvark TherapeuticsN/A$10.44-3.2%$32.80+214.2%N/A$233.89MN/A0.0018News CoverageAnalyst RevisionFENCAdherex Technologies1.7796 of 5 stars$8.20-1.9%$13.33+62.6%+51.9%$232.53M$33.30M-19.5210News CoverageAnalyst ForecastAnalyst RevisionGap DownGALTGalectin Therapeutics2.403 of 5 stars$3.90+9.2%$6.00+53.8%+77.5%$228.70MN/A-6.099ALECAlector3.8955 of 5 stars$2.13-5.3%$4.17+95.6%-52.5%$227.73M$100.56M-1.84270GNFTGENFIT2.1585 of 5 stars$4.50+12.8%$9.00+100.0%-0.8%$225.11M$67.00M0.00120News CoveragePositive NewsAnalyst ForecastAnalyst RevisionGap UpHigh Trading VolumeTVRDTvardi Therapeutics1.5448 of 5 stars$24.74+3.1%$64.25+159.7%N/A$224.66M$7.14M0.0080News Coverage Related Companies and Tools Related Companies scPharmaceuticals Alternatives Allogene Therapeutics Alternatives Sagimet Biosciences Alternatives SOPHiA GENETICS Alternatives Aardvark Therapeutics Alternatives Adherex Technologies Alternatives Galectin Therapeutics Alternatives Alector Alternatives GENFIT Alternatives Tvardi Therapeutics Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:GANX) was last updated on 8/24/2025 by MarketBeat.com Staff From Our PartnersTrump’s betrayal exposedTrump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | SponsoredTrump’s “new dollar” could shock Americans"I Made Millions in the Tech Boom. Here's Where I'd Put My Money Today" This man has called some of the big...Stansberry Research | SponsoredHere's the last trade you should make before heading out for the weekend tomorrow.On a quiet Friday afternoon, one trader spotted an overlooked stock. He bought shares. He shut down his ...Timothy Sykes | SponsoredTake a look at this picture ...A strange investment secret — discovered just a few short weeks before this image was taken — correctly predic...Weiss Ratings | SponsoredTrump’s SHOCKING Plan to Create MASSIVE Wealth for AmericansJames Altucher says Donald Trump just made a move so surprising, it could go down as the most lucrative presid...Paradigm Press | Sponsored[No Brainer Gold Play]: “Show me a better investment.”A Historic Gold Announcement Is About to Rock Wall Street? For months, sharp-eyed analysts have watched the...Golden Portfolio | SponsoredTrump set to Boost Social Security Checks by 400%?If you're collecting or planning to collect social security... You should see this presentation about Presi...InvestorPlace | SponsoredIs Elon's empire crumbling?The Tesla Shock Nobody Sees Coming While headlines scream "Tesla is doomed"... Jeff Brown has uncovered ...Brownstone Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Gain Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Gain Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
MarketBeat All Access